Eterna Therapeutics

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

NTN Buzztime, Inc. provides bar and restaurant social entertainment and integrated marketing platform. Trusted by bars & restaurants since 1984, Buzztime integrates trivia, card & sports games with in- and out-of-venue marketing, messaging & communication tools. Over 4 million registered players competing in more than 50 million games each year spread the word and invite friends and family to their favorite Buzztime location to enjoy an evening of fun and competition. Buzztime is delighted to announce the launch of BEOND, the first social, mobile, entertainment platform for bars and restaurants.

IRX Therapeutics develops immune therapies designed to activate a patient’s immune system to defeat cancer and related diseases. IRX Therapeutics’ is focused on making cancer treatments better. The lead platform technology, IRX-2, is thought to broadly restore the immune system by overcoming cancer-induced immune suppression. The Company believes that its products can play an important role in helping a wide range of cancer treatments improve and extend the lives of patients. It was founded in 1994 and is headquartered in New York.